tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Fredericks S et al. | Multidrug resistance gene-1 (MDR-1) haplotypes have a minor influence on tacrolimus dose requirements. | 2006 | Transplantation | pmid:16969296 |
| Gralla J and Wiseman AC | Tacrolimus/sirolimus versus tacrolimus/mycophenolate in kidney transplantation: improved 3-year graft and patient survival in recent era. | 2009 | Transplantation | pmid:19502965 |
| Garcia-Criado FJ et al. | Tacrolimus (FK506) down-regulates free radical tissue levels, serum cytokines, and neutrophil infiltration after severe liver ischemia. | 1997 | Transplantation | pmid:9293871 |
| Suzuki H et al. | Induction of transplantation tolerance in adult rats by vascularized spleen transplantation. | 1997 | Transplantation | pmid:9293881 |
| Satterthwaite R et al. | Incidence of new-onset hypercholesterolemia in renal transplant patients treated with FK506 or cyclosporine. | 1998 | Transplantation | pmid:9484771 |
| Francavilla A et al. | Inhibition of liver, kidney, and intestine regeneration by rapamycin. | 1992 | Transplantation | pmid:1371198 |
| Lee D et al. | Age and Early Graft Function Relate With Risk-Benefit Ratio of Allogenic Islet Transplantation Under Antithymocyte Globulin-Mycophenolate Mofetil-Tacrolimus Immune Suppression. | 2017 | Transplantation | pmid:27779572 |
| Wozniak LJ et al. | Donor-specific HLA Antibodies Are Associated With Late Allograft Dysfunction After Pediatric Liver Transplantation. | 2015 | Transplantation | pmid:26038872 |
| Kuypers DR et al. | Maintenance immunosuppressive agents as risk factors for BK virus nephropathy: the need for true drug exposure measurements. | 2010 | Transplantation | pmid:20555228 |
| Moxey-Mims MM | Increased incidence of insulin-dependent diabetes mellitus in pediatric renal transplant patients receiving tacrolimus (FK506) | 1999 | Transplantation | pmid:10440413 |
| Guethoff S et al. | Ten-year results of a randomized trial comparing tacrolimus versus cyclosporine a in combination with mycophenolate mofetil after heart transplantation. | 2013 | Transplantation | pmid:23423270 |
| Miyakoshi S et al. | Tacrolimus as prophylaxis for acute graft-versus-host disease in reduced intensity cord blood transplantation for adult patients with advanced hematologic diseases. | 2007 | Transplantation | pmid:17700155 |
| Naesens M et al. | The impact of renal allograft function on exposure and elimination of mycophenolic acid (MPA) and its metabolite MPA 7-O-glucuronide. | 2007 | Transplantation | pmid:17700162 |
| McGhee B et al. | Therapeutic use of an extemporaneously prepared oral suspension of tacrolimus in pediatric patients. | 1997 | Transplantation | pmid:9326429 |
| Huang E et al. | Alemtuzumab induction in deceased donor kidney transplantation. | 2007 | Transplantation | pmid:17984833 |
| Kato T et al. | Randomized trial of steroid-free induction versus corticosteroid maintenance among orthotopic liver transplant recipients with hepatitis C virus: impact on hepatic fibrosis progression at one year. | 2007 | Transplantation | pmid:17984834 |
| Yoshimura N et al. | The direct effect of FK506 and rapamycin on interleukin 1(beta) and immunoglobulin production in vitro. | 1994 | Transplantation | pmid:7517078 |
| Tuteja S et al. | The effect of gut metabolism on tacrolimus bioavailability in renal transplant recipients. | 2001 | Transplantation | pmid:11397967 |
| Kahan BD | An immunosuppressive triumvirate to minimize renal injuries associated with calcineurin antagonist therapy. | 1999 | Transplantation | pmid:10428260 |
| Washburn K et al. | Steroid elimination 24 hours after liver transplantation using daclizumab, tacrolimus, and mycophenolate mofetil. | 2001 | Transplantation | pmid:11726831 |
| Reichenspurner H et al. | Optimization of the immunosuppressive protocol after lung transplantation. | 1999 | Transplantation | pmid:10428269 |
| Pilmore HL et al. | Tacrolimus for the treatment of gout in renal transplantation: two case reports and review of the literature. | 2001 | Transplantation | pmid:11726837 |
| Muthukumar T et al. | HIV-infected kidney graft recipients managed with an early corticosteroid withdrawal protocol: clinical outcomes and messenger RNA profiles. | 2013 | Transplantation | pmid:23503504 |
| Ishizuka J et al. | Effects of FK506 and cyclosporine on dynamic insulin secretion from isolated dog pancreatic islets. | 1993 | Transplantation | pmid:7506454 |
| Murase N et al. | FK506 suppression of heart and liver allograft rejection. II: The induction of graft acceptance in rats. | 1990 | Transplantation | pmid:1700504 |
| Shapiro R et al. | Pediatric renal transplantation under tacrolimus-based immunosuppression. | 1999 | Transplantation | pmid:10075598 |
| Mor E et al. | Reversal of severe FK506 side effects by conversion to cyclosporine-based immunosuppression. | 1994 | Transplantation | pmid:7519800 |
| Morikawa K et al. | The distinct effects of FK506 on the activation, proliferation, and differentiation of human B lymphocytes. | 1992 | Transplantation | pmid:1281561 |
| Jain A et al. | Conversion to neoral for neurotoxicity after primary adult liver transplantation under tacrolimus. | 2000 | Transplantation | pmid:10653398 |
| Textor SC et al. | Systemic and renal hemodynamic differences between FK506 and cyclosporine in liver transplant recipients. | 1993 | Transplantation | pmid:7685934 |
| First MR et al. | New-onset diabetes after transplantation (NODAT): an evaluation of definitions in clinical trials. | 2013 | Transplantation | pmid:23619735 |
| Ninova D et al. | Acute nephrotoxicity of tacrolimus and sirolimus in renal isografts: differential intragraft expression of transforming growth factor-beta1 and alpha-smooth muscle actin. | 2004 | Transplantation | pmid:15316360 |
| Berg UB et al. | Renal function before and long after liver transplantation in children. | 2001 | Transplantation | pmid:11544422 |
| Murase N et al. | Hamster-to-rat heart and liver xenotransplantation with FK506 plus antiproliferative drugs. | 1993 | Transplantation | pmid:7682735 |
| Gruessner RW et al. | Mycophenolate mofetil in pancreas transplantation. | 1998 | Transplantation | pmid:9721799 |
| Emond JC et al. | Improved results of living-related liver transplantation with routine application in a pediatric program. | 1993 | Transplantation | pmid:7682738 |
| Woodle ES et al. | Tacrolimus therapy for refractory acute renal allograft rejection: definition of the histologic response by protocol biopsies. | 1996 | Transplantation | pmid:8878382 |
| Kershner RP and Fitzsimmons WE | Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. | 1996 | Transplantation | pmid:8878385 |
| Tanaka A et al. | Living related liver transplantation across ABO blood groups. | 1994 | Transplantation | pmid:7522363 |
| Devlin J et al. | Nitric oxide generation. A predictive parameter of acute allograft rejection. | 1994 | Transplantation | pmid:7522365 |
| Vafadari R et al. | Pharmacodynamic analysis of tofacitinib and basiliximab in kidney allograft recipients. | 2012 | Transplantation | pmid:22960764 |
| Thomas PG et al. | Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immunological risk renal transplantation. | 2007 | Transplantation | pmid:17565326 |
| McCarthy SA et al. | The effects of immunosuppressive drugs on the regulation of activation-induced apoptotic cell death in thymocytes. | 1992 | Transplantation | pmid:1384186 |
| Nakajima K et al. | Prolongation of cardiac xenograft survival in rats treated with 15-deoxyspergualin alone and in combination with FK506. | 1988 | Transplantation | pmid:2454521 |
| Hughes JR et al. | Blood levels of TGFbeta1 in liver transplant recipients receiving either tacrolimus or micro-emulsified cyclosporine. | 1999 | Transplantation | pmid:10480422 |
| Cacciarelli TV et al. | Management of posttransplant lymphoproliferative disease in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy. | 1998 | Transplantation | pmid:9808490 |
| Wissing KM et al. | Effect of atorvastatin therapy and conversion to tacrolimus on hypercholesterolemia and endothelial dysfunction after renal transplantation. | 2006 | Transplantation | pmid:17006324 |
| Gruessner RW et al. | Over 500 solitary pancreas transplants in nonuremic patients with brittle diabetes mellitus. | 2008 | Transplantation | pmid:18192910 |
| Griffith BP et al. | A prospective randomized trial of FK506 versus cyclosporine after human pulmonary transplantation. | 1994 | Transplantation | pmid:7512292 |
| Sun S et al. | Effect of tacrolimus on hemodynamics and absorption of experimental small intestinal transplants. | 1996 | Transplantation | pmid:8633368 |